Company
Melbourne, VIC
Every investor coverage indicates participated in a round St. Vincent's Hospital raised.
Companies St. Vincent's Hospital acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Professor Mark Cook | Neurologist | Startup Daily |
| Dr Chris Hayward | Heart Failure Cardiologist | GBS Ventures |
Stories naming St. Vincent's Hospital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of Melbourne-based biotech Neurala Biosciences, founded by two researchers turning DMT and harmala compounds into medicines, covering its origins, grant and investor backing totalling $4.5m, and planned first-in-human studies.
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
Epiminder raised A$18 million in bridge funding for its epilepsy monitoring implant, backed by existing shareholders including Cochlear, after completing an A$18 million Series A in October 2021.
Epi-Minder has completed a $16 million bridge round with its existing shareholders to fund expanded clinical trials, product development and manufacturing of its long-term epilepsy monitoring device.
Sunshine Heart's chief executive reports to shareholders on the C-Pulse trial: halfway through its US feasibility study, first two minimally invasive implants completed and new hospitals in Australia, Canada and the US joining.